GlassScriptPhysician profile
Luis M Galvez
NPI 1326039231
$6,655.61
in general payments reported to CMS, 2019-2025
42 companies · $833 in 2025
The $833 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $307 · 2021: $1,114 · 2022: $1,388 · 2023: $1,128 · 2024: $1,062 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,939 · Education: $84.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,939.05 |
| Education | $84.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,172.81 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $953.19 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $479.75 | 2019-2025 | Entyvio, Takhzyro |
| Celgene Corporation | $451.21 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $344.61 | 2019-2024 | Stelara |
| Pfizer INC. | $275.18 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $216.27 | 2019-2024 | Ocaliva |
| Allergan, INC. | $178.42 | 2019 | |
| Merck Sharp & Dohme LLC | $170.26 | 2020-2023 | Dificid, Zinplava |
| Aimmune Therapeutics, INC. | $128.34 | 2023-2025 | Zenpep |
| Celltrion USA INC. | $126.57 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Genzyme Corporation | $111.36 | 2022-2024 | |
| Madrigal Pharmaceuticals | $96.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Vivus LLC | $89.73 | 2022-2025 | Qsymia, Pancreaze |
| Regeneron Healthcare Solutions, INC. | $86.95 | 2022-2024 | Dupixent |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Galvez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.